Brief: Athenex Presents Interim Data From Study Of KUR-502 In Lymphoma And Leukemia
25/04/2022 13:08
April 25 (Reuters) - Athenex Inc ATNX.O :
* ATHENEX PRESENTS INTERIM DATA FROM PHASE 1 ANCHOR STUDY OF
KUR-502 (ALLOGENEIC CD19 CAR-NKT CELLS) IN RELAPSED OR
REFRACTORY LYMPHOMA AND LEUKEMIA AT THE 2022 TRANSPLANTATION &
CELLULAR (“TANDEM”) MEETINGS OF ASTCT AND CIBMTR
Source text for Eikon: ID:nGNXb6zng5
Further company coverage: ATNX.O
((Reuters.Briefs@thomsonreuters.com;))